肝脏内胆管癌 (iCCA) 系统治疗的新选择
Rafał Becht1, Michał P Wasilewicz2
1Department of Clinical Oncology, Chemotherapy and Cancer Immunotherapy Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Medicina (Kaunas, Lithuania)
|June 28, 2023
概括
肝脏内胆管癌 (iCCA) 是一种胆道癌,发病率越来越高. 虽然手术是首要的,但化学疗法和免疫疗法等全身疗法对于不可切除或晚期病例至关重要,正在研究新的点.
科学领域:
- 肝胆道恶性瘤 肝胆道恶性瘤
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
背景情况:
- 在全球范围内,肝脏内胆管癌 (iCCA) 的发病率正在上升.
- 炎症变化与iCCA的发展密切相关.
- 手术切除仅限于诊断时不到30%的患者.
研究的目的:
- 审查目前肝脏内胆管癌的全身治疗选择.
- 强调在先进或渐进的ICCA中需要有效的治疗方法.
- 讨论iCCA的新兴治疗目标.
主要方法:
- 对iCCA系统治疗的当前临床实践和文献的审查.
- 标准辅助疗法和一线治疗方法的分析.
- 确定新的治疗点和途径.
主要成果:
- 开普西他化疗是iCCA的标准辅助治疗.
- 系统化疗,单独或与免疫疗法 (durvalumab, pembrolizumab) 一起使用,用于不可手术或转移性iCCA.
- 新的治疗点包括IDH,FGFR2和BRAF突变正在研究中.
结论:
- 对大多数iCCA患者来说,有效的全身治疗是必不可少的.
- 对于在一线治疗后进展的患者来说,急需治疗方法.
- 针对基因突变的向治疗是iCCA管理的有希望的未来方向.
相关概念视频
Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


